{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T18:40:06Z","timestamp":1747075206520,"version":"3.40.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12029-025-01236-6","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T05:34:09Z","timestamp":1747028049000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Concurrent Coprimary KIT Exon 17 and BRAF Mutations in a Small Intestinal GI Stromal Tumor\u2014A Case Report"],"prefix":"10.1007","volume":"56","author":[{"given":"Hashim","family":"Ishfaq","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misbah Younus","family":"Soomro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bakhtawar","family":"Masood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashida","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmin Abdul","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"key":"1236_CR1","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1097\/PAS.0000000000000418","volume":"39","author":"S Rossi","year":"2015","unstructured":"Rossi S, Gasparotto D, Miceli R, et al. KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST: a population-based study. Am J Surg Pathol. 2015;39:922\u201330.","journal-title":"Am J Surg Pathol"},{"key":"1236_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12957-018-1532-1","volume":"16","author":"C Jumniensuk","year":"2018","unstructured":"Jumniensuk C, Charoenpitakchai M. Gastrointestinal stromal tumor: clinicopathological characteristics and pathologic prognostic analysis. World J Surg Oncol. 2018;16:1\u20139.","journal-title":"World J Surg Oncol"},{"key":"1236_CR3","first-page":"1259","volume":"152","author":"LG Kindblom","year":"1998","unstructured":"Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998;152:1259.","journal-title":"Am J Pathol"},{"key":"1236_CR4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0002-9440(10)63279-8","volume":"165","author":"RB West","year":"2004","unstructured":"West RB, Corless CL, Chen X, et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol. 2004;165:107\u201313.","journal-title":"Am J Pathol"},{"key":"1236_CR5","doi-asserted-by":"publisher","first-page":"144","DOI":"10.21037\/jgo.2018.08.20","volume":"10","author":"TM Parab","year":"2019","unstructured":"Parab TM, DeRogatis MJ, Boaz AM, Grasso SA, Issack PS, Duarte DA, Urayeneza O, Vahdat S, Qiao JH, Hinika GS. Gastrointestinal stromal tumors: a comprehensive review. J Gastrointest Oncol. 2019;10:144.","journal-title":"J Gastrointest Oncol"},{"key":"1236_CR6","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1158\/1078-0432.CCR-11-2230","volume":"18","author":"C Miranda","year":"2012","unstructured":"Miranda C, Nucifora M, Molinari F, et al. KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin Cancer Res. 2012;18:1769\u201376.","journal-title":"Clin Cancer Res"},{"key":"1236_CR7","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/nrc3143","volume":"11","author":"CL Corless","year":"2011","unstructured":"Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer. 2011;11:865\u201378.","journal-title":"Nat Rev Cancer"},{"key":"1236_CR8","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1158\/1078-0432.CCR-22-3980","volume":"29","author":"H Joensuu","year":"2023","unstructured":"Joensuu H, Wardelmann E, Eriksson M, et al. KIT and PDGFRA mutations and survival of gastrointestinal stromal tumor patients treated with adjuvant imatinib in a randomized trial. Clin Cancer Res. 2023;29:3313\u20139.","journal-title":"Clin Cancer Res"},{"key":"1236_CR9","doi-asserted-by":"publisher","first-page":"839","DOI":"10.3109\/07357907.2010.494322","volume":"28","author":"A Wozniak","year":"2010","unstructured":"Wozniak A, Floris G, Debiec-Rychter M, Sciot R, Sch\u00f6ffski P. Implications of mutational analysis for the management of patients with gastrointestinal stromal tumors and the application of targeted therapies. Cancer Invest. 2010;28:839\u201348.","journal-title":"Cancer Invest"},{"key":"1236_CR10","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.2147\/OTT.S81558","volume":"8","author":"G Spitaleri","year":"2015","unstructured":"Spitaleri G, Biffi R, Barberis M, Fumagalli C, Toffalorio F, Catania C, Noberasco C, Lazzari C, De Marinis F, De Pas T. Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K). Onco Targets Ther. 2015;8:1997\u20132003.","journal-title":"Onco Targets Ther"},{"key":"1236_CR11","doi-asserted-by":"publisher","unstructured":"Kalfusova A, Linke Z, Kalinova M, Krskova L, Hilska I, Szabova J, Vicha A, Kodet R. Gastrointestinal stromal tumors - summary of mutational status of the primary\/secondary KIT\/PDGFRA mutations, BRAF mutations and SDH defects. Pathol Res Pract. 2019. https:\/\/doi.org\/10.1016\/J.PRP.2019.152708.","DOI":"10.1016\/J.PRP.2019.152708."},{"key":"1236_CR12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/ijc.11374","volume":"107","author":"CR Rossi","year":"2003","unstructured":"Rossi CR, Mocellin S, Mencarelli R, Foletto M, Pilati P, Nitti D, Lise M. Gastrointestinal stromal tumors: from a surgical to a molecular approach. Int J Cancer. 2003;107:171\u20136.","journal-title":"Int J Cancer"},{"key":"1236_CR13","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231192388\/ASSET\/IMAGES\/LARGE\/10.1177_17588359231192388-FIG2.JPEG","author":"C Serrano","year":"2023","unstructured":"Serrano C, Mart\u00edn-Broto J, Asencio-Pascual JM. 2023 GEIS guidelines for gastrointestinal stromal tumors. Ther Adv Med Oncol. 2023. https:\/\/doi.org\/10.1177\/17588359231192388\/ASSET\/IMAGES\/LARGE\/10.1177_17588359231192388-FIG2.JPEG.","journal-title":"Ther Adv Med Oncol"},{"key":"1236_CR14","doi-asserted-by":"publisher","first-page":"5078","DOI":"10.1158\/1078-0432.CCR-20-1706","volume":"26","author":"C Serrano","year":"2020","unstructured":"Serrano C, George S. Gastrointestinal stromal tumor: challenges and opportunities for a new decade. Clin Cancer Res. 2020;26:5078\u201385.","journal-title":"Clin Cancer Res"},{"key":"1236_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-685","author":"M Nannini","year":"2014","unstructured":"Nannini M, Astolfi A, Urbini M, et al. Integrated genomic study of quadruple-WT GIST (KIT\/PDGFRA\/SDH\/RAS pathway wild-type GIST). BMC Cancer. 2014. https:\/\/doi.org\/10.1186\/1471-2407-14-685.","journal-title":"BMC Cancer"},{"key":"1236_CR16","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/gcc.20589","volume":"47","author":"NP Agaram","year":"2008","unstructured":"Agaram NP, Wong GC, Guo T, Maki RG, Singer S, DeMatteo RP, Besmer P, Antonescu CR. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer. 2008;47:853\u20139.","journal-title":"Genes Chromosomes Cancer"},{"key":"1236_CR17","doi-asserted-by":"publisher","first-page":"30109","DOI":"10.18632\/oncotarget.8768","volume":"7","author":"S Rossi","year":"2016","unstructured":"Rossi S, Sbaraglia M, Dell\u2019Orto MC, et al. Concomitant KIT\/BRAF and PDGFRA\/BRAF mutations are rare events in gastrointestinal stromal tumors. Oncotarget. 2016;7:30109\u201318.","journal-title":"Oncotarget"},{"key":"1236_CR18","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1309\/AJCPPCKGA2QGBJ1R","volume":"133","author":"I Hostein","year":"2010","unstructured":"Hostein I, Faur N, Primois C, Boury F, Denard J, Emile JF, Bringuier PP, Scoazec JY, Coindre JM. BRAF mutation status in gastrointestinal stromal tumors. Am J Clin Pathol. 2010;133:141\u20138.","journal-title":"Am J Clin Pathol"},{"key":"1236_CR19","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1158\/1535-7163.MCT-18-1224","volume":"18","author":"T Muhlenberg","year":"2019","unstructured":"Muhlenberg T, Ketzer J, Heinrich MC, et al. Kit-dependent and KIT-independent genomic heterogeneity of resistance in gastrointestinal stromal tumors - TORC1\/2 inhibition as salvage strategy. Mol Cancer Ther. 2019;18:1985\u201396.","journal-title":"Mol Cancer Ther"},{"key":"1236_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/ESMOOPEN-2018-000335","author":"L Mavroeidis","year":"2018","unstructured":"Mavroeidis L, Metaxa-Mariatou V, Papoudou-Bai A, et al. Comprehensive molecular screening by next generation sequencing reveals a distinctive mutational profile of KIT\/ PDGFRA genes and novel genomic alterations: results from a 20-year cohort of patients with GIST from north-western Greece. ESMO Open. 2018. https:\/\/doi.org\/10.1136\/ESMOOPEN-2018-000335.","journal-title":"ESMO Open"},{"key":"1236_CR21","doi-asserted-by":"publisher","first-page":"iv68","DOI":"10.1093\/annonc\/mdy095","volume":"29","author":"PG Casali","year":"2018","unstructured":"Casali PG, Abecassis N, Bauer S, et al. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv68\u201378.","journal-title":"Ann Oncol"},{"key":"1236_CR22","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1016\/j.humpath.2008.06.025","volume":"39","author":"H Joensuu","year":"2008","unstructured":"Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008;39:1411\u20139.","journal-title":"Hum Pathol"},{"key":"1236_CR23","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S1470-2045(11)70299-6","volume":"13","author":"H Joensuu","year":"2012","unstructured":"Joensuu H, Vehtari A, Riihim\u00e4ki J, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol. 2012;13:265\u201374.","journal-title":"Lancet Oncol"},{"key":"1236_CR24","unstructured":"Gastrointestinal stromal tumors - guidelines detail. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1507. Accessed 23 Feb 2025."},{"key":"1236_CR25","doi-asserted-by":"publisher","first-page":"528","DOI":"10.3109\/0284186X.2011.636753","volume":"51","author":"HJ Kang","year":"2012","unstructured":"Kang HJ, Ryu MH, Kim KM, et al. Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): the Korean GIST Study Group (KGSG) study. Acta Oncol. 2012;51:528\u201336.","journal-title":"Acta Oncol"},{"key":"1236_CR26","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/labinvest.2009.78","volume":"89","author":"T Ishikawa","year":"2009","unstructured":"Ishikawa T, Nakai N, Liu NN, et al. In vivo effect of imatinib on progression of cecal GIST-like tumors in exon 17-type c-kit knock-in mice. Lab Invest. 2009;89:1161\u20138.","journal-title":"Lab Invest"},{"key":"1236_CR27","doi-asserted-by":"publisher","first-page":"466","DOI":"10.21037\/jgo.2016.09.15","volume":"8","author":"PJ Oppelt","year":"2017","unstructured":"Oppelt PJ, Hirbe AC, van Tine BA. Gastrointestinal stromal tumors (GISTs): point mutations matter in management, a review. J Gastrointest Oncol. 2017;8:466.","journal-title":"J Gastrointest Oncol"},{"key":"1236_CR28","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/j.1582-4934.2009.00983.x","volume":"14","author":"LF Lopes","year":"2010","unstructured":"Lopes LF, Bacchi CE. Imatinib treatment for gastrointestinal stromal tumour (GIST). J Cell Mol Med. 2010;14:42\u201350.","journal-title":"J Cell Mol Med"},{"key":"1236_CR29","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1200\/JCO.2013.51.2046","volume":"32","author":"CL Corless","year":"2014","unstructured":"Corless CL, Ballman KV, Antonescu CR, et al. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. J Clin Oncol. 2014;32:1563\u201370.","journal-title":"J Clin Oncol"},{"key":"1236_CR30","doi-asserted-by":"publisher","first-page":"6105","DOI":"10.1158\/1078-0432.CCR-14-1677","volume":"20","author":"A Wozniak","year":"2014","unstructured":"Wozniak A, Rutkowski P, Sch\u00f6ffski P, et al. Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a european multicenter analysis based on ConticaGIST. Clin Cancer Res. 2014;20:6105\u201316.","journal-title":"Clin Cancer Res"},{"key":"1236_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/J.PRP.2020.153171","author":"K Ja\u0161ek","year":"2020","unstructured":"Ja\u0161ek K, V\u00e1\u0148ov\u00e1 B, Grend\u00e1r M, \u0160tanclov\u00e1 A, Sz\u00e9pe P, Horn\u00e1kov\u00e1 A, Holubekov\u00e1 V, Plank L, Lasabov\u00e1 Z. BRAF mutations in KIT\/PDGFRA positive gastrointestinal stromal tumours (GISTs): is their frequency underestimated? Pathol Res Pract. 2020. https:\/\/doi.org\/10.1016\/J.PRP.2020.153171.","journal-title":"Pathol Res Pract"},{"key":"1236_CR32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.1258","author":"R Ricci","year":"2016","unstructured":"Ricci R, Martini M, Cenci T, Antinori A, Cassano A, Larocca LM. Case of rectal GI stromal tumor demonstrating that KIT and PDGFRA mutations are not always mutually exclusive. J Clin Oncol. 2016. https:\/\/doi.org\/10.1200\/JCO.2013.49.1258.","journal-title":"J Clin Oncol"},{"key":"1236_CR33","first-page":"1379","volume":"23","author":"P Mazzola","year":"2008","unstructured":"Mazzola P, Spitale A, Banfi S, Mazzucchelli L, Frattini M, Bordoni A. Epidemiology and molecular biology of gastrointestinal stromal tumors (GISTs): a population-based study in the South of Switzerland, 1999\u20132005. Histol Histopathol. 2008;23:1379\u201386.","journal-title":"Histol Histopathol"},{"key":"1236_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/S11864-021-00827-2","author":"BR Halle","year":"2021","unstructured":"Halle BR, Johnson DB. Defining and targeting BRAF mutations in solid tumors. Curr Treat Options Oncol. 2021. https:\/\/doi.org\/10.1007\/S11864-021-00827-2.","journal-title":"Curr Treat Options Oncol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01236-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-025-01236-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01236-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T18:03:14Z","timestamp":1747072994000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-025-01236-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1236"],"URL":"https:\/\/doi.org\/10.1007\/s12029-025-01236-6","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"type":"print","value":"1941-6628"},{"type":"electronic","value":"1941-6636"}],"subject":[],"published":{"date-parts":[[2025,5,12]]},"assertion":[{"value":"29 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"We obtained informed consent from the patient for the publication of this case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The authors affirm that the patient has provided informed consent for the publication of their data and of the images in Fig.\u00a0.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"116"}}